S. Guard

发表

In vitro behavior and UV response of melanocytes derived from carriers of CDKN2A mutations and MC1R variants

B. Hernando, V. Swope, S. Guard, 2018, Pigment cell & melanoma research.

Multiomic Analysis Reveals Disruption of Cholesterol Homeostasis by Cannabidiol in Human Cell Lines

Douglas A. Chapnick, Jeremy R. Jacobsen, Xuedong Liu, 2020, bioRxiv.

Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins

S. Guard, N. Ratner, R. Hennigan, 2019, Science Signaling.

The interaction of the NK1 receptor antagonist CP‐96,345 with L‐type calcium channels and its functional consequences

S. Guard, G. Woodruff, A. McKnight, 1993, British journal of pharmacology.

Stimulation ofangiogenesis bysubstance Pandinterleukin- 1in theratanditsinhibition byNK1orinterleukin- 1receptor antagonists

S. Guard, 1993 .

Characterisation of [125I][MePhe7]neurokinin B binding to tachykinin NK3 receptors: evidence for interspecies variance.

S. Guard, G. Woodruff, Z. Madden, 1994, European journal of pharmacology.

[125i]Neurokinin A labels pharmacologically distinct populations of NK2 binding sites in hamster and rabbit urinary bladder

S. Guard, R. Franks, K. Watling, 1993 .

An SAR study for the non-peptide substance P receptor (NK1) antagonist, CP-96,345.

S. Guard, W. Howson, K. Watling, 1992 .

Evidence for Two Types of Tachykinin Receptors on Cholinergic Neurons of the Guinea Pig Ileum Myenteric Plexus a

S. Watson, S. Guard, A. McKnight, 1991, Annals of the New York Academy of Sciences.

Label-Free Immunoprecipitation Mass Spectrometry Workflow for Large-scale Nuclear Interactome Profiling.

Christopher C. Ebmeier, S. Guard, W. Old, 2019, Journal of visualized experiments : JoVE.

Stimulation of angiogenesis by substance P and interleukin‐1 in the rat and its inhibition by NK1 or interleukin‐1 receptor antagonists

S. Guard, T. Fan, G. Gresham, 1993, British journal of pharmacology.

Tachykinin receptor types: Classification and membrane signalling mechanisms

S. Watson, S. Guard, 1991, Neurochemistry International.

Rational design of high affinity tachykinin NK1 receptor antagonists.

S. Guard, A. McKnight, S. Boyle, 1994, Bioorganic & medicinal chemistry.

On the presence of NK2 receptor subtypes in peripheral and central tissues

R. Zarnegar, S. Guard, J. Krause, 1993, Regulatory Peptides.

Pharmacological characterization of tachykinin‐stimulated inositol phospholipid hydrolysis in peripheral tissues

S. Guard, N. Suman-Chauhan, B. Williams, 1990, British journal of pharmacology.

Neurokinin3‐receptors are linked to inositol phospholipid hydrolysis in the guinea‐pig ileum longitudinal muscle‐myenteric plexus preparation

S. Guard, K. Watling, S. Watson, 1988, British journal of pharmacology.

Pharmacological analysis of [3H]‐senktide binding to NK3 tachykinin receptors in guinea‐pig ileum longitudinal muscle‐myenteric plexus and cerebral cortex membranes

H. Too, S. Guard, J. Maggio, 1990, British journal of pharmacology.

Evidence for neurokinin-3 receptor-mediated tachykinin release in the guinea-pig ileum.

S. Watson, S. Guard, 1987, European journal of pharmacology.

Receptor subtypes or species homologues: relevance to drug discovery.

S. Watson, S. Guard, M. Caulfield, 1993, Trends in pharmacological sciences.

Rational design of high affinity tachykinin NK2 receptor antagonists.

S. Guard, A. McKnight, S. Boyle, 1994, Bioorganic & medicinal chemistry.

The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair

Christopher C. Ebmeier, D. Taatjes, S. Guard, 2018, bioRxiv.

Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long‐term extension study

G. Karsenty, R. Dmochowski, S. Guard, 2017, Neurourology and urodynamics.

The non-peptide tachykinin NK2 receptor antagonist SR 48968 interacts with human, but not rat, cloned tachykinin NK3 receptors.

S. Guard, D. Oxender, L. H. Wu, 1994, Biochemical and biophysical research communications.

Calcitonin gene-related peptide (hCGRPα) binding sites in the nucleus accumbens. Atypical structural requirements and marked phylogenic differences

S. Guard, R. Quirion, A. Fournier, 1991, Brain Research.

Structure-activity requirements of bombesin for gastrin-releasing peptide- and neuromedin B-preferring bombesin receptors in rat brain.

S. Guard, W. Howson, K. Watling, 1993, European journal of pharmacology.

693 Consistent long-term efficacy and safety of onabotulinumtoxinA in patients with neurogenic detrusor overactivity: Final results of repeated treatments up to 4 years

G. Karsenty, R. Dmochowski, S. Guard, 2014 .

583 OnabotulinumtoxinA reduces urinary incontinence and improves quality of life in overactive bladder patients regardless of use of clean intermittent catheterisation or the presence of urinary tract infection

S. Guard, K. Everaert, D. Sussman, 2014 .

The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair

Christopher C. Ebmeier, D. Taatjes, S. Guard, 2018, Scientific Reports.